Renal effects of molecular targeted therapies in oncology: a review by the Cancer and the Kidney International Network (C-KIN). - Wikidata - wikimedia - TriplyDB

Renal effects of molecular targeted therapies in oncology: a review by the Cancer and the Kidney International Network (C-KIN).

Renal effects of molecular targeted therapies in oncology: a review by the Cancer and the Kidney International Network (C-KIN).

http://www.wikidata.org/entity/Q38367232

about

Acute kidney injury in critically ill cancer patients: an update Chemotherapy of ovarian cancer in elderly patients Systemic therapy of non-colorectal gastrointestinal malignancies in the elderly Synthesis of a stable and orally bioavailable englerin analogue.A post hoc analysis of dalteparin versus oral anticoagulant (VKA) therapy for the prevention of recurrent venous thromboembolism (rVTE) in patients with cancer and renal impairment.Onco-nephrology: a decalogue.Safe and Effective Sarcoma Therapy through Bispecific Targeting of EGFR and uPAR.Nephrotoxicity of anticancer treatment.Osteoporosis, bone mineral density and CKD-MBD: treatment considerations.Cancer and the kidney: dangereoux liasons or price paid for the progress in medicine?The Inverse Association between the Baseline Renal Function and Overall Survival in Patients with Metastatic Renal Cell Carcinoma Treated with Molecular-Targeted Agents.Predictive factors of renal toxicities related to anti-VEGFR multikinase inhibitors in phase 1 trials.Mechanisms of VEGF (Vascular Endothelial Growth Factor) Inhibitor-Associated Hypertension and Vascular Disease.Changes in Renal Function of Patients with Metastatic Renal Cell Carcinoma During Treatment with Molecular-Targeted Agents.

P2860

Q26740168-19369E2F-1752-408B-94C3-DFA25D7824C9 Q26771397-D9F0A67F-C2B9-4EF9-A554-38C5F8A690E4 Q26771399-010DE324-9FE7-432B-A7E7-B2356078CABE Q36887630-AF4089A8-2531-4B72-B15C-0CAF07BF2CC0 Q37293267-F4CC05A5-2A1D-4523-9BFB-D58E9D7B1D20 Q38581085-A9DA031A-8B08-43E9-ACD1-C02FD266F8AD Q38963363-FB38F990-76D4-44BD-9565-E3543088A182 Q39198933-ADA397F2-FB8E-4FDA-B59C-3103876979F6 Q39255870-79697558-865C-4B3A-AE8A-9ED0DAC26DC4 Q42371674-7FEDA8EB-2848-48F9-8AD3-BF57BB3FDC20 Q47144097-23F78665-94EC-4047-8E52-D19735A23946 Q48274997-6C652C42-4620-4377-8D43-2CCA73AF0D5D Q49568718-701BA5FF-5A02-43B8-99A4-15A3F9A5A0E0 Q52906446-EF798C57-4CEB-4FB8-800B-E062633204B9

P2860

Renal effects of molecular targeted therapies in oncology: a review by the Cancer and the Kidney International Network (C-KIN).

http://www.wikidata.org/entity/Q38367232

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年学术文章

@wuu

2015年学术文章

@zh-cn

2015年学术文章

@zh-hans

2015年学术文章

@zh-my

2015年学术文章

@zh-sg

2015年學術文章

@yue

2015年學術文章

@zh

2015年學術文章

@zh-hant

name

Renal effects of molecular tar ...... International Network (C-KIN).

@en

type

label

Renal effects of molecular tar ...... International Network (C-KIN).

@en

prefLabel

Renal effects of molecular tar ...... International Network (C-KIN).

@en

P1433

Q38367232-7B53EC3C-4EBD-4380-8E0F-D01AA7161220

P1476

Q38367232-ACECEABF-E058-451A-BF7C-AD1572B29B37

P2093

Q38367232-3D601C38-5132-46FB-AACA-D223F6661E26

Q38367232-53978BD1-2B6E-4233-8606-D1378D221B9D

Q38367232-5A510277-E508-481D-8675-3B3055F42736

Q38367232-644BF2B9-4D74-4BF5-91A8-FE9A706E91E1

Q38367232-A72F2455-EBF5-4E40-A2E0-11B3F3892A5D

Q38367232-D5D6B505-26F3-4A68-8052-985B1006231B

Q38367232-E06FB0F5-0B4B-48ED-9804-CFBA26633081

Q38367232-F580D51C-343D-4FC6-BFED-FCC462B21374

P2860

Q38367232-005E7543-D17A-43AB-82C4-6C311B6FB682

Q38367232-06167685-62E1-485C-996C-12BE36FC9252

Q38367232-06508DE8-A917-4A86-9A6B-AEC9D93DCD6A

Q38367232-067BA56D-295D-435D-973A-C3D4268A96DF

Q38367232-0E8AEFF5-201F-4550-829A-C1CABBFA5A7E

Q38367232-154FAE58-51D4-4711-A64A-2869BE4D1D16

Q38367232-1C88EB9D-EAE9-4AB0-94D1-E2DA202DDBBD

Q38367232-1E15DC62-8E70-4C1D-8C84-CE8485C6D9C2

Q38367232-22D7B3DF-BBE6-4528-9C5A-8C42C9DA14BB

Q38367232-23702F70-3DE3-4D73-BA56-BA9C1744968A

P304

Q38367232-D3D848A6-8A57-43B9-AEEC-8376F477C623

P31

Q38367232-4C947646-9AC7-4D9D-A2E9-4B50FC6D6F9B

P356

Q38367232-1F9D57F7-89A3-410A-96B5-719644F177CA

P433

Q38367232-B7CD3861-F1BE-4307-AF2B-547CB5659D69

P478

Q38367232-3155DDE1-7548-4E36-ADA1-C8FFE59BF514

P50

Q38367232-4701DC12-6C60-4306-8ACB-7AF9A5E03EAF

Q38367232-4CCE9732-41D9-4607-9025-3E8F83406828

Q38367232-AD14A290-29BA-4016-BAF3-8F21D85DA00E

Q38367232-B3CF1CDB-F605-48AB-B8B4-D6B1368040B2

P577

Q38367232-F78D5DF6-0F6E-499A-B247-17EB635FD8DD

P5875

Q38367232-34C9F601-B3A9-4EF0-A646-F68B2FFA6A3F

P698

Q38367232-B909CC6C-BEF4-431F-A6E2-3A40D1273058

P356

P1433

Annals of Oncology

P1476

Renal effects of molecular tar ...... International Network (C-KIN).

@en

P2093

B Humphreys

http://www.w3.org/2001/XMLSchema#string

E Cohen

http://www.w3.org/2001/XMLSchema#string

F Scotté

http://www.w3.org/2001/XMLSchema#string

G Deray

http://www.w3.org/2001/XMLSchema#string

H Wildiers

http://www.w3.org/2001/XMLSchema#string

J Rey

http://www.w3.org/2001/XMLSchema#string

M Aapro

http://www.w3.org/2001/XMLSchema#string

M Dooley

http://www.w3.org/2001/XMLSchema#string

P2860

VEGF inhibition and renal thrombotic microangiopathy

Safety, activity, and immune correlates of anti-PD-1 antibody in cancer

CH5424802 (RO5424802) for patients with ALK-rearranged advanced non-small-cell lung cancer (AF-001JP study): a single-arm, open-label, phase 1-2 study.

Crizotinib versus chemotherapy in advanced ALK-positive lung cancer.

Cisplatin and fluorouracil with or without panitumumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck (SPECTRUM): an open-label phase 3 randomised trial.

Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer

Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates

Safety and pharmacokinetics of escalated doses of weekly intravenous infusion of CCI-779, a novel mTOR inhibitor, in patients with cancer.

A phase 2 study with a daily regimen of the oral mTOR inhibitor RAD001 (everolimus) in patients with metastatic clear cell renal cell cancer.

First-line trastuzumab plus epirubicin and cyclophosphamide therapy in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: cardiac safety and efficacy data from the Herceptin, Cyclophosphamide, and Epirubicin (H

P304

1677-1684

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/ANNONC/MDV136

http://www.w3.org/2001/XMLSchema#string

P433

8

http://www.w3.org/2001/XMLSchema#string

P478

26

http://www.w3.org/2001/XMLSchema#string

P50

Vincent Launay-Vacher

Stuart M Lichtman

Gilberto de Castro

P577

2015-03-03T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

273132162

http://www.w3.org/2001/XMLSchema#string

P698

25735315

http://www.w3.org/2001/XMLSchema#string